A post hoc analysis of tumor samples from patients with HCC enrolled in the GO30140 phase 1b trial and the IMbrave-150 trial showed that molecular correlates associated with improved clinical response to atezolizumab/bevacizumab included pre-existing immunity (high expression of CD274, T-effector signature and intratumoral CD8+ T cell density), the high expression of VEGFR-2, T regulatory cells, and myeloid inflammatory signatures. This evidence concerns the gene CD8A and neoplasm.